Global Stroke Prevention in Atrial Fibrillation SPAF Treatment Market Insights and Forecast to 2028

BUY CHAPTERS

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Global Market Insights and Sales Trends 2024

Q: How big is the stroke prevention in atrial fibrillation spaf treatment market?

Atrial fibrillation AF now a days has become a common and serious condition affecting almost 12 of the total population of age group 65 years and above.Market Analysis and Insights Global Stroke Prevention in Atrial Fibrillation SPAF Treatment MarketThe global Stroke Prevention in Atrial Fibrillation SPAF Treatment market size is projected to reach US million by 2028 from US million in 2021 at a CAGR of during 20222028.Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death.With industrystandard accuracy in analysis and high data integrity the report makes a brilliant attempt to unveil key opportunities available in the global Stroke Prevention in Atrial Fibrillation SPAF Treatment market to help players in achieving a strong market position.

Q: Who are the key players in the stroke prevention in atrial fibrillation spaf treatment market?

Some of the key players are AF, Age group, Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol–Myers Squibb, Pfizer Inc, Daiichi Sankyo, Gilead, China, India, Others.

Code: QYRE-Auto-22I2149

Report

December 2023

Pages:86

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market

Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above.

The global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Surgical Centers,, are propelling Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market. Oral Direct Thrombin Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral Direct Factor Xa Inhibitors segment is estimated at % CAGR for the next seven-year period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Stroke Prevention in Atrial Fibrillation (SPAF) Treatment sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment covered in this report include Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo and Gilead, etc.

The global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

Boehringer Ingelheim

Bayer

Johnson & Johnson

Bristol-Myers Squibb

Pfizer

Daiichi-Sankyo

Gilead

Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, by region:

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, Segment by Type:

Oral Direct Thrombin Inhibitors

Oral Direct Factor Xa Inhibitors

Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, by Application

Hospitals

Clinics

Ambulatory Surgical Centers

Scope of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market Report

Report Metric	Details
Report Name	Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market
CAGR	5%
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

1 Market Overview of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment

1.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Overview

1.1.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Scope

1.1.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Status and Outlook

1.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2018-2029)

1.4 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Region (2018-2023)

1.5 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

1.6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

1.6.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

1.6.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

1.6.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

1.6.5 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029)

2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market by Type

2.1 Introduction

2.1.1 Oral Direct Thrombin Inhibitors

2.1.2 Oral Direct Factor Xa Inhibitors

2.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Type (2018-2023)

2.2.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Type (2018-2029)

3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Overview by Application

3.1 Introduction

3.1.1 Hospitals

3.1.2 Clinics

3.1.3 Ambulatory Surgical Centers

3.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Application (2018-2023)

3.2.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Breakdown by Application (2018-2029)

4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Competition Analysis by Players

4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2022)

4.3 Date of Key Players Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market

4.4 Global Top Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Headquarters and Area Served

4.5 Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service

4.6 Competitive Status

4.6.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 Boehringer Ingelheim

5.1.1 Boehringer Ingelheim Profile

5.1.2 Boehringer Ingelheim Main Business

5.1.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.1.4 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.1.5 Boehringer Ingelheim Recent Developments

5.2 Bayer

5.2.1 Bayer Profile

5.2.2 Bayer Main Business

5.2.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.2.4 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.2.5 Bayer Recent Developments

5.3 Johnson & Johnson

5.3.1 Johnson & Johnson Profile

5.3.2 Johnson & Johnson Main Business

5.3.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.3.4 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.3.5 Bristol-Myers Squibb Recent Developments

5.4 Bristol-Myers Squibb

5.4.1 Bristol-Myers Squibb Profile

5.4.2 Bristol-Myers Squibb Main Business

5.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.4.4 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.4.5 Bristol-Myers Squibb Recent Developments

5.5 Pfizer

5.5.1 Pfizer Profile

5.5.2 Pfizer Main Business

5.5.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.5.4 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.5.5 Pfizer Recent Developments

5.6 Daiichi-Sankyo

5.6.1 Daiichi-Sankyo Profile

5.6.2 Daiichi-Sankyo Main Business

5.6.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.6.4 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.6.5 Daiichi-Sankyo Recent Developments

5.7 Gilead

5.7.1 Gilead Profile

5.7.2 Gilead Main Business

5.7.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

5.7.4 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) & (2018-2023)

5.7.5 Gilead Recent Developments

6 North America

6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2029)

6.2 U.S.

6.3 Canada

7 Europe

7.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Dynamics

11.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Industry Trends

11.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers

11.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges

11.4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

FEATURED COMPANIES

List of Tables

Table 1. Global Market Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Region (2018-2023)

Table 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2023)

Table 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2024-2029)

Table 11. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2023)

Table 24. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2024-2029)

Table 26. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2022)

Table 39. Date of Key Players Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market

Table 40. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players Headquarters and Area Served

Table 41. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service

Table 42. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. Boehringer Ingelheim Basic Information List

Table 45. Boehringer Ingelheim Description and Business Overview

Table 46. Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 47. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Boehringer Ingelheim (2018-2023)

Table 48. Boehringer Ingelheim Recent Developments

Table 49. Bayer Basic Information List

Table 50. Bayer Description and Business Overview

Table 51. Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 52. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Bayer (2018-2023)

Table 53. Bayer Recent Developments

Table 54. Johnson & Johnson Basic Information List

Table 55. Johnson & Johnson Description and Business Overview

Table 56. Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 57. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Johnson & Johnson (2018-2023)

Table 58. Johnson & Johnson Recent Developments

Table 59. Bristol-Myers Squibb Basic Information List

Table 60. Bristol-Myers Squibb Description and Business Overview

Table 61. Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 62. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Bristol-Myers Squibb (2018-2023)

Table 63. Bristol-Myers Squibb Recent Developments

Table 64. Pfizer Basic Information List

Table 65. Pfizer Description and Business Overview

Table 66. Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 67. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Pfizer (2018-2023)

Table 68. Pfizer Recent Developments

Table 69. Daiichi-Sankyo Basic Information List

Table 70. Daiichi-Sankyo Description and Business Overview

Table 71. Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 72. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Daiichi-Sankyo (2018-2023)

Table 73. Daiichi-Sankyo Recent Developments

Table 74. Gilead Basic Information List

Table 75. Gilead Description and Business Overview

Table 76. Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Products, Services and Solutions

Table 77. Revenue (US$ Million) in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business of Gilead (2018-2023)

Table 78. Gilead Recent Developments

Table 79. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2023) & (US$ Million)

Table 80. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2024-2029) & (US$ Million)

Table 81. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2023) & (US$ Million)

Table 82. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2024-2029) & (US$ Million)

Table 83. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 84. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2018-2023) & (US$ Million)

Table 85. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2024-2029) & (US$ Million)

Table 86. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2018-2023)

Table 87. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2024-2029)

Table 88. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 89. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2023) & (US$ Million)

Table 90. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2024-2029) & (US$ Million)

Table 91. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 92. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2018-2023) & (US$ Million)

Table 93. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2024-2029) & (US$ Million)

Table 94. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Trends

Table 95. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers

Table 96. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges

Table 97. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions: 2022 VS 2029

Figure 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of Oral Direct Thrombin Inhibitors

Figure 11. Global Oral Direct Thrombin Inhibitors Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of Oral Direct Factor Xa Inhibitors

Figure 13. Global Oral Direct Factor Xa Inhibitors Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Type: 2022 & 2029

Figure 15. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2029)

Figure 16. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2029)

Figure 17. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2029)

Figure 18. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2029)

Figure 19. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2018-2029)

Figure 20. Hospitals Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 21. Clinics Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 22. Ambulatory Surgical Centers Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 23. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Application: 2022 & 2029

Figure 24. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2029)

Figure 25. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2029)

Figure 26. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2029)

Figure 27. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2029)

Figure 28. Middle East and Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2018-2029)

Figure 29. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 30. Global Top 5 and Top 10 Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share in 2022

Figure 31. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2018-2029)

Figure 32. U.S. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 33. Canada Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 34. Germany Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 35. France Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 36. U.K. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 37. Italy Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 38. Russia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 39. Nordic Countries Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 40. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2018-2029)

Figure 41. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 42. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 43. South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 44. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 45. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 46. Australia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 47. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2018-2029)

Figure 48. Mexico Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 49. Brazil Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 50. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2018-2029)

Figure 51. Turkey Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 52. Saudi Arabia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 53. UAE Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2018-2029) & (US$ Million)

Figure 54. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Global Market Insights and Sales Trends 2024

Published Date: December 2023

Report Code: QYRE-Auto-22I2149

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Global Market Insights and Sales Trends 2024

FEATURED COMPANIES

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market Size

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market

Report Objectives

Key Features of The Study:

Scope of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment - Market Report

Core Chapters

FEATURED COMPANIES

RELATED REPORTS